Biologics and Biosimilars: staying current

Innovator biologics, biosimilars, biobetters, intended copies and non-biologic complex drugs (NBCD). Regulatory pathway aside policies from HTA bodies and payers signal they will treated as generic-like. Keep in mind that biosimilar entries may impact a therapeutic area in which you participate whether or not you market a biologic medicine. What can Canada learn from the EU experience?

Know More:

Resourcing pipeline product launches

Need to secure resources for your next product launch? Whether your company is a Start Up or is already established in Canada, Pangaea has developed detailed critical paths and established processes to objectively evaluate the commercial potential and required resources for a successful commercialization

Know More:

Commercial Readiness

Struggling to stay on top of all of the changes in the healthcare environment? The volume, pace and implications of change are causing brand teams, departments and entire organizations to be reactive. The Pangaea team proactively monitors changes in this increasingly complex healthcare environment and can help you to make well informed decisions

Know more: